**Name of journal: World Journal of Diabetes**

**ESPS Manuscript NO: 7875**

**Columns:** **Randomized Controlled Trial**

**Impact of chronic disease self-management programs on type 2 diabetes management in primary care**

Forjuoh SN *et al*. Impact of chronic disease self-management programs

**Samuel N Forjuoh, Marcia G Ory, Luohua Jiang, Ann M Vuong, Jane N Bolin**

**Samuel N Forjuoh,** Department of Family and Community Medicine, Scott and White Healthcare, College of Medicine, Texas A and M Health Science Center, Temple, TX 76504, United States

**Samuel N Forjuoh, Marcia G Ory,** Department of Health Promotion and Community Health Sciences, School of Rural Public Health, Texas A and M Health Science Center, College Station, TX 77843, United States

**Samuel N Forjuoh, Ann M Vuong, Luohua Jiang,** Department of Epidemiology and Biostatistics, School of Rural Public Health, Texas A and M Health Science Center, College Station, TX 77843, United States

**Jane N Bolin,** Department of Health Policy and Management, School of Rural Public Health, Texas A and M Health Science Center, College Station, TX 77843, United States

**Author contributions**: Forjuoh SN, Ory MG and Bolin JN conceptualized the study, acquired funding, provided supervision, interpreted the data, drafted the manuscript, and reviewed the final version; Vuong AM and Jiang L analyzed the data and assisted with data interpretation and manuscript preparation.

**Supported by** The National Institutes of Health’s National Institute on Minority Health and Health Disparities, No. #1P20MD002295

**Correspondence to: Samuel N Forjuoh, MD, MPH, DrPH, FGCP,** Department of Family and Community Medicine, Scott and White Healthcare, College of Medicine, Texas A and M Health Science Center, 1402 West Ave H, Temple, TX 76504, United States. [sforjuoh@sw.org](mailto:sforjuoh@sw.org)

**Telephone**: +1-254-7717695 **Fax:** +1-254-7718493

**Received:**  December 4, 2013 **Revised:** April 10, 2014

**Accepted:** April 16, 2014

**Published online:**

**Abstract**

**AIM**: To assess the effectiveness of the Chronic Disease Self-Management Program (CDSMP) on glycated hemoglobin (HbA1c) and selected self-reported measures.

**METHODS**: We compared patients who received a diabetes self-care behavioral intervention, the CDSMP developed at the Stanford University, with controls who received usual care on their HbA1c and selected self-reported measures, including diabetes self-care activities, health-related quality of life (HRQOL), pain and fatigue. The subjects were a subset of participants in a randomized controlled trial that took place at seven regional clinics of a university-affiliated integrated healthcare system of multi-specialty group practice between January 2009 and June 2011. The primary outcome was change in HbA1c from randomization to 12 mo. Data were analyzed using multilevel statistical models and linear mixed models to provide unbiased estimates of intervention effects.

**RESULTS**: Demographic and baseline clinical characteristics were generally comparable between the two groups. The average baselines HbA1c in the CDSMP and control groups were 9.4% and 9.2%, respectively. Significant reductions in HbA1c were seen at 12 mo for the two groups, with adjusted changes around 0.6% (*P* < 0.0001), but the reductions did not differ significantly between the two groups (*P* = 0.885). Few significant differences were observed in participants’ diabetes self-care activities. No significant differences were observed in the participants’ HRQOL, pain, or fatigue measures.

**CONCLUSION**: The CDSMP intervention may not lower HbA1c any better than good routine care in an integrated healthcare system. More research is needed to understand the benefits of self-management programs in primary care in different settings and populations.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words**: Type 2 diabetes; Self-management; Chronic Disease Self-Management Program; Glycemic control; Glycated hemoglobin, HbA1c; Chronic disease

**Core tip:** Diabetes is a serious chronic disease. One of the most studied evidence-based behavioral or self-care programs targeting chronic conditions including diabetes is the Stanford Chronic Disease Self-Management Program (CDSMP). Although the CDSMP has been studied extensively, its impact on glycemic control has not been thoroughly evaluated in a randomized controlled trial to date. To the best of our knowledge, this is first study to evaluate the effectiveness of the CDSMP in a randomized controlled trial. Our finding that the CDSMP intervention may not lower HbA1c any better than good routine care in an integrated healthcare system calls for further research.

Forjuoh SN, Ory MG, Jiang L, Vuong AM, Bolin JN. Impact of chronic disease self-management programs on type 2 diabetes management in primary care

**Available from:**

**DOI:**

**INTRODUCTION**

Diabetes is a serious chronic condition affecting millions of people worldwide. According to estimates by the World Health Organization, about 350 million people have diabetes globally[1]. Diabetes has severe and significant health and economic impact on all nations. It is the 6th leading cause of death in Canada and the 7th leading cause of death in the US, costing an estimated $174 billion[2,3]. The bulk of this cost is attributable to the serious long-term complications associated with the condition including limb amputations, blindness, coronary health disease, stroke, and kidney disease[3]. Type 2 diabetes accounts for 90%-95% of all diabetes[3]. Although type 2 diabetes is more prevalent among people aged 40 years or older, the prevalence among younger populations is increasing dramatically because of the rise in obesity and physical inactivity in children and the youth[4].

Supportive programs to enhance patient self-care have been touted as a pre-requisite to diabetes management in spite of differences in individual needs to cope with this debilitating condition[5]. The traditional didactic models of care that involved teaching patients to improve the knowledge of their health condition is giving way to the current models that focus on behavioral or self-care approaches aimed at providing patients with the skills and strategies to promote and change their behavior[6]. In fact, several national organizations including the American Diabetes Association and the American Association of Diabetes Educators consider self-care an essential component of effective diabetes management [7-9].

One of the most studied evidence-based behavioral or self-care programs targeting chronic conditions is the Chronic Disease Self-Management Program (CDSMP). Developed at the Stanford University, the program offers the potential to improve overall health of individuals with chronic conditions, while preventing further decline in their general health status[10-12]. Designed as a 6-wk, community-based self-care education program, it focuses on assisting participants to gain confidence or self-efficacy and acquire skills to better manage their chronic conditions. It is taught by trained leaders using a structured protocol.

The CDSMP has been found to be highly effective in improving general health and lowering hospitalization rates[10]. It has therefore been implemented worldwide for several chronic conditions such as heart disease, lung disease, arthritis, and diabetes as well as evaluated in various settings including the United States, Canada, United Kingdom, Australia, New Zealand, Bangladesh, China, Hong Kong, and the Netherlands[13-20]. While the original CDSMP validation study found improvements in general health status, health behaviors, and healthcare utilization[10], the findings of more recent studies from a variety of self-management programs have been inconsistent[5,21-27]. A recent literature review of randomized controlled trials comparing self-management support interventions for general chronic diseases versus usual care revealed mixed results. While positive findings were found regarding self-efficacy, less positive ones were found for quality-of-life measures[5]. Also although the CDSMP has been studied extensively, its impact on glycemic control has not been thoroughly assessed. In particular, its effectiveness on glycemic control has not been evaluated in a randomized controlled trial in the US to date. A recent study concluded that the CDSMP is a useful and appropriate program for lowering HbA1c among those out of control[28]. However, this was a longitudinal study with no comparison group. Another related study found the CDSMP to improve lifestyle behaviors among patients with type 2 diabete[23,29]. But again this was a single-group design.

The aim of this study was to assess the effectiveness of the CDSMP on glycemic control and selected self-reported measures among patients with type 2 diabetes in a large integrated healthcare organization in central Texas that serves large racially/ethnically populations.

**MATERIALS AND METHODS**

***Design***

This study was a comparison of one intervention arm, the CDSMP, and the control arm from an open-label, 4-arm randomized controlled trial that was designed to evaluate the effectiveness of two different T2DM self-care interventions (implemented singly and in combination) on glycemic control. Designed with the acknowledgment that both patients and researchers would be aware of the random assignment, the study protocol consisted of screening potential subjects for eligibility, randomizing them to one of four study arms, and following them over a 24-mo period. However, the primary end-point was change in glycated hemoglobin (HbA1c) from randomization/baseline to 12 mo of follow-up. The current study reported here focuses on participants in two of the four original study arms.

The study protocol was approved by the Institutional Review Boards (IRB) of Scott and White Healthcare System and Texas A and M Health Science Center. All qualified participants accepted the conditions of the study and gave informed written consent at enrollment**/**orientation. Enrollment occurred January 2009-June 2011 and data collection was completed in July 2012. We adhered to the CONSORT protocol[30] and registered the trial with clinicaltrials.gov (NCT01221090).

***Setting, participants, and recruitment***

Participants represent a subset of subjects that was recruited from seven participating clinics of a large integrated healthcare system, a university-affiliated, multi-specialty group practice associated with a 250000-member Health Maintenance Organization in central Texas. Potential participants were identified through electronic medical records if they: (1) had a diagnosis of T2DM; (2) were ≥ 18 years; (3) had a lab assessed HbA1c value ≥ 7.5% (≥ 58 mmol/mol) within the last six months; and (4) were able to communicate in English. Subjects were excluded if they: (1) had documented reports of alcoholism or drug abuse; (2) were pregnant or planning to become pregnant within 12 mon; or (3) were unwilling to sign an informed consent. Recruitment was solicited by physicians within the seven clinics who agreed to invite their patients to participate in the study.

Physicians were provided with IRB approved invitation-to-participate letters and a list of their T2DM patients meeting the threshold HbA1c level at their last visit. Contact was initiated with potential subjects through physician-sent letters, describing the study and requesting a completed screening enrollment card if interested. Subjects who returned a screening enrollment card were contacted by project coordinators, who provided additional information and screened them to determine eligibility. To verify the inclusion and exclusion criteria, subject permission was obtained to review their medical records. Other recruitment strategies included oral referrals by physicians and patient educators and posting messages in waiting areas of study clinics.

Lab assessments were continuously monitored at each phase of the study recruitment to ensure that enrolled participants had HbA1c values ≥ 7.5% (≥ 58 mmol/mol) within the last six months since individuals who previously met this criterion may no longer fulfill that requirement at orientation. A follow-up telephone interview was conducted to determine participation interest. Lab results were screened to ensure participant met qualifying HbA1c and if needed, tests were scheduled.

***Intervention***

Participants randomized to the CDSMP arm were invited to attend a 6-wk, classroom-based program for diabetes self-management. The effectiveness of the CDSMP has been described elsewhere[10]. With the goal of increasing self-efficacy to ultimately decrease chronic disease related symptoms and avoidable healthcare utilization, the CDSMP teaches participants techniques to facilitate enhanced decision making, action planning, and effective communication. CDSMP workshops were hosted in clinical environments and community-based settings. While fidelity to the individual classes was not monitored, CDSMP license requires that lay leaders use pre-scripted materials and that experienced master trainers/lay leaders (who underwent the four-day training program) lead the workshops.

Participants randomized to the control arm did not receive any treatment other than their usual clinical diabetes care, along with some publicly available Texas Diabetes Council patient education materials.

***Data collection***

Study measures were obtained at orientation/baseline, six months, and 12 mo of follow-up. Participants received monetary compensation in the form of a gift card for travel expenses and time, consisting of $20 at orientation and at the 12-mo follow-up visit.

At orientation, a questionnaire was administered to obtain several information including: (1) demographics such as age, gender, and race/ethnicity; (2) diabetes self-care activities monitoring (number of days, 0-7, that any specific self-care activity was performed in the past week) as measured by the Summary of Diabetes Self-Care Activities (SDSCA) instrument; (3) self-reported health-related quality of life (HRQOL) measures (*e.g.*, number of days physical/mental health was not good); and (4) pain and fatigue measures (on a scale of 1-10, 1 indicating none and 10 severe). Questionnaires were administered every 6 mo. However, as our primary end point was 12-mo, analyses were only conducted for this time period.

Anthropometric data were obtained at orientation and at subsequent follow-up visits. Height in inches was measured without shoes. Weight was measured in pounds on a balance beam scale or an electronic scale without shoes. Body mass index (BMI) was computed from height and weight measurements. Blood pressures were recorded with either a mercury sphygmomanometer or a validated automated device. Participants who were unable to come in for their follow-up appointments had their height, weight, and blood pressure data abstracted from electronic health records (EHRs). Measures recorded fell within the range of 10 d prior to and 45 d after participants’ scheduled follow-up dates. This was done to obtain participant visits as close to their target dates as possible, but also allow for enough time after the target date to accommodate for scheduling errors (*i.e.*, missed appointments, rescheduling).

Measures of HbA1c were collected from EHRs dating back six months prior to orientation to the last day of study participation (45 d after the 12-mo follow-up period). If a participant did not have any HbA1c value within the EHR for any particular follow-up visit, a lab test was scheduled to obtain a measure. Of the HbA1c collected six months prior to orientation, the value measured closest to the orientation date was considered as the baseline HbA1c value. HbA1c values that were measured on dates preceding the baseline HbA1c were not included; *i.e.*, HbA1c values included in the analysis were those collected since the baseline HbA1c and until the last day of study participation.

***Definition of a completed follow-up participation***

A participant was considered to have completed a follow-up if there was an available HbA1c within the designated follow-up period, *i.e*., within the cut-off dates, defined as within 45 d after the scheduled follow-up dates. For the 6-mo follow-up measure, if at least one HbA1c was available after baseline and before the 6-mo cut-off, the participant was considered to have completed a follow-up. For the 12-mo follow-up measure, the designated range was between the 6-month cut-off date and the 12-mo cut-off date. Participants who were unable to complete an assessment at one time period were not excluded from future assessments. For instance, if a participant did not have any HbA1c measured within the specified time period for their 6-mo follow-up but had one available for their 12-mo follow-up they were considered to have completed the 12-mo follow-up, but not the 6-mo.

***Outcome measures***

The primary study outcome measure was change in HbA1c from randomization to 12 mo of follow-up. Secondary outcome measures included BMI and blood pressure, along with several self-management behavioral measures (*e.g.*, foot care) from randomization to 12 mo of follow-up.

***Statistical analysis***

Analysis was based on intent-to-treat. Descriptive statistics were used to describe baseline demographic, anthropometric, and clinical characteristics by study arm. Analysis of variance (ANOVA) was used to compare average changes in self-management behaviors between study arms. To determine whether the treatment had an effect on the rate of change in HbA1c level over time, we used linear mixed models that included time as a continuous variable. A spatial power covariance structure with time as the distance measure accounted for the time-series correlation among repeated measurements on each subject. Forward selection was utilized, in which powers of time were added one at a time to the base model including treatment group effects only. Time and treatment effects were then added gradually and evaluated with likelihood ratio tests to assess any effect modification. The final mixed model included time, time squared, treatment group, and the interaction between time and treatment group as fixed effects. HbA1c values included in the analysis were those falling within the time frame of six months prior to orientation until the 12-mo follow-up cut-off point.

**RESULTS**

***Subject enrollment, participation and retention***

The flow diagram of participant enrollment and disposition in the trial has been described elsewhere[31]. Of the subjects randomized, 101 entered the CDSMP arm and 95 entered the control arm. Of the participants assigned to the CDSMP, 75.6% attended 4 of 6 sessions required for successful completion.

***Demographic data and baseline comparison of study population***

Demographic and baseline clinical characteristics were generally comparable between the two groups (Table 1). The mean age of participants was 57.6 ± 10.9 years. Slightly more than a third (36.4%) was of minority status, self-reporting as either African American or Hispanic. The majority of participants received post-secondary education; 40% had attended some college or vocational school, 20% were college graduates, and 13% had completed higher forms of education. Approximately one-third reported annual incomes greater than $50000, while almost 40% reported annual incomes between $25000 and $49999.

An overwhelming majority (92.9%) of the participants were either overweight or obese, with a mean BMI of 34.3 ± 7.4 kg/m2. While measures of systolic blood pressure were comparable among study arms, with a mean of 134.8 ± 19.3 mmHg, measures of diastolic blood pressure were significantly different (*P* < 0.002). The mean baseline HbA1c for participants was 9.3% ± 1.6% and did not differ significantly among the four groups.

Table 2 summarizes participants’ diabetes self-care activity (DSCA) monitoring, health related quality of life (HRQOL) measures, and pain and fatigue measures at baseline. Participants in the control arm reported checking their feet more frequently than those in the CDSMP arm (*P* = 0.04). Although participants in the control group reported inspecting the inside of their shoes more frequently and also tended to report fewer unhealthy physical days and experience less limited days due to physical and mental health, these did not reach statistical significance (*P* ≥ 0.05).

***Changes in Hba1c from baseline to 12 mo***

There were modest but statistically significant reductions in HbA1c from baseline to 12 mo of follow-up. The results of the linear mixed model are presented in Table 3. The adjusted reductions in HbA1c over the 12 mo of follow-up for the CDSMP and control groups were 0.559% and 0.576%, respectively (*P* < 0.0001). However, the interaction term of the treatment group and time was not statistically significant (*P* = 0.885), implying no significant difference in HbA1c reductions by treatment assignment.

***Changes in DSCA monitoring, HRQOL measures, and pain and fatigue measures***

The mean difference in the number of days (within the last 7 d), from baseline to 12 mo of follow-up that participants reported using specific diabetes self-care activity features, measured by the Summary of Diabetes Self-Care Activities instrument, to assist with diabetes self-care activity monitoring were compared between the CDSMP and control arms (table not shown). While there were no differences on 12 of the 14 self-care indicators, participants in the control arm had a higher rate of change in checking their feet than those in the CDSMP arm (increase of 0.28 d/mo *vs.* 0.20 d/mo; *P* = 0.02). Similarly, participants in the control arm reported an increase of 0.15 d/mo eating 5 or more servings of fruits and vegetables compared to an increase of 0.01 d/mo reported by those in the CDSMP arm (*P* = 0.02).

**DISCUSSION**

In this study, we sought to assess the effectiveness of the Stanford Chronic Disease Self-Management program (CDSMP) on glycated hemoglobin (HbA1c) and selected self-reported measures among patients with type 2 diabetes who were out of control. We found no significant differences between the CDSMP intervention and usual care in this integrated healthcare system. To the best of our knowledge, this is first study to evaluate the effectiveness of the CDSMP in a randomized controlled trial in the United States. It is also one of the first studies to evaluate and compare these interventions in a racially/ethnically diverse population in a practice setting outside of testing done by the original program developers. It therefore provides important exploratory data, shaping our knowledge and understanding of factors which may be important to minority and ethnic populations in adopting diabetes self-management techniques.

Our results corroborate the findings of others that participation in the CDSMP may be associated with better glycemic control[28]. However, a comparison with the control group indicates that usual care might do equally well. Study findings need to be tempered due to the possibility of methodological confounds such as unaccounted group demographic and health differences at baselines, relatively small samples sizes, better awareness among those in a clinical trial or high quality routine diabetes care that emphasizes the importance of glycemic control is unknown. For example, participants in this study were, on average, younger than those studied in other recent CDSMP studies[23,29], and the controls in this study appeared slightly healthier and better educated than their counterparts in the CDSMP intervention which might have made them more receptive to both clinical and community-based diabetes self-management and obesity prevention messages. Further, the Scott and White Healthcare, the study settings, employs diabetes educators for their patients with diabetes and along with their dedicated endocrinologists exceeds the recommendations for diabetes care set by the Texas Diabetes Association.

Other study limitations need to be noted. First, our subjects were selected from a randomized controlled trial with three interventions, restricting the numbers available in any one group. Second, post-hoc analysis showed that we were somewhat under-powered: we only had 60% power to detect a difference of 0.5% HbA1c reduction between the two groups at the current sample size. Other future analyses should focus on randomizing a larger number of participants in the treatment arm being investigated. Third, there were notable differences between the intervention and control groups with the control group appearing to be healthier at baseline. Fourth, there was attrition in terms of treatment completion for the intervention group (75.6% attended 4 of 6 sessions required for successful completion) as well as differential research attrition between the two groups (14.9% or 15 participants in the treatment group and 23.2% or 22 participants in the control group did not have 12 mo data). Finally, this study was conducted in only one integrated health care system limiting generalizability to other settings and populations.

There is also a debate in the self-management field regarding whether generic versus disease specific self-management is more beneficial[32,33]. While our view was that a generic program would be valuable for patients experiencing several comorbidities including diabetes, more positive results might have been observed if the diabetes specific chronic disease self-management program was utilized (which was not evidence-based at the time of initial program selection for English speaking patients)[34].

In conclusion, we found in this study that although a behavioral intervention such as the CDSMP can result in some modest improvements in glycemic control, the same improvements may be found among participants that receive usual care. The reduction in HbA1c levels found in our control group that received usual care suggests that good routine care in an integrated healthcare system can also lead to better glycemic control. More research is needed to understand the benefits of self-management programs both independently and in conjunction with primary care. For example, are there settings where self-management programs might be especially needed, *e.g.*, in medically underserved areas? And what kinds of participants might improve most with self-management programs. Such knowledge is important for providing better tailoring diabetes care to patients.

**ACKNOWLEDGEMENTS**

We thank Dawn Begaye for study coordination, Ann Robertson for data abstraction, and Phyllis Davis for administrative duties.

**COMMENTS**

***Background***

The Stanford Chronic Disease Self-Management Program (CDSMP) represents one of the most studied evidence-based behavioral or self-care programs for chronic diseases including diabetes.

***Research frontiers***

The CDSMP has been found to be highly effective in improving the general health of people with several chronic conditions such as heart disease and arthritis. Recent evidence indicates that the CDSMP is a useful and appropriate program for lowering glycated hemoglobin (HbA1c) among people with type 2 diabetes who are out of control.

***Innovations and breakthroughs***

This study demonstrated that the CDSMP may not lower HbA1c among people with type 2 diabetes any better than good routine care in an integrated healthcare system.

***Applications***

Findings from this study show that people with type 2 diabetes managed with good routine care in an integrated healthcare system can also have good glycemic control. Nonetheless more research is needed to understand the benefits of self-care programs in primary care.

***Peer review***

The study by Forjuoh *et al*, aimed to assess the effectiveness of the Chronic Diseases Self-management Program on the metabolic control. This is an interesting investigation on the practical point of view.

**REFERENCES**

1 **World Health Organization.** Diabetes. Geneva: World Health Organization, 2012 (Accessed on 27th November 2013). Available from: URL: http: //www.who.int/mediacentre/factsheets/fs312/en/index.html.

2 **Brod M**, Wolden M, Groleau D, Bushnell DM. Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2. *J Med Econ* 2014; **17**: 11-20 [PMID: 24199622]

3 **Zhuo X**, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. *Am J Prev Med* 2013; **45**: 253-261 [PMID: 23953350 DOI: 10.1016/j.amepre.2013.04.017]

4 **Caprio S**. Development of type 2 diabetes mellitus in the obese adolescent: a growing challenge. *Endocr Pract* 2013; **18**: 791-795 [PMID: 23047931 DOI: 10.4158/EP12142.RA]

5 **Franek J**. Self-management support interventions for persons with chronic disease: an evidence-based analysis. *Ont Health Technol Assess Ser* 2013; **13**: 1-60 [PMID: 24194800]

6 . Behavioural interventions for type 2 diabetes: an evidence-based analysis. *Ont Health Technol Assess Ser* 2009; **9**: 1-45 [PMID: 23074526]

7 . Standards of medical care in diabetes--2011. *Diabetes Care* 2011; **34 Suppl 1**: S11-S61 [PMID: 21193625 DOI: 10.2337/dc11-S011]

8 **Funnell MM**, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B, Maryniuk M, Peyrot M, Piette JD, Reader D, Siminerio LM, Weinger K, Weiss MA. National Standards for diabetes self-management education. *Diabetes Care* 2011; **34 Suppl 1**: S89-S96 [PMID: 21193633 DOI: 10.2337/dc11-S089]

9 **Handelsman Y**, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovič L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. *Endocr Pract* 2011; **17 Suppl 2**: 1-53 [PMID: 21474420 DOI: 10.4158/EP.17.S2.1]

10 **Lorig KR**, Sobel DS, Stewart AL, Brown BW, Bandura A, Ritter P, Gonzalez VM, Laurent DD, Holman HR. Evidence suggesting that a chronic disease self-management program can improve health status while reducing hospitalization: a randomized trial. *Med Care* 1999; **37**: 5-14 [PMID: 10413387 DOI: 10.1097/00005650-199901000-00003]

11 **Lorig KR**, Ritter P, Stewart AL, Sobel DS, Brown BW, Bandura A, Gonzalez VM, Laurent DD, Holman HR. Chronic disease self-management program: 2-year health status and health care utilization outcomes. *Med Care* 2001; **39**: 1217-1223 [PMID: 11606875 DOI: 10.1097/00005650-200111000-00008]

12  **Foster G,** Taylor SJ, Eldridge SE, Ramsay J, Griffiths CJ. Self-management education programmes by lay leaders for people with chronic conditions. *Cochrane Database Syst Rev* 2007; **17:** CD005108

13 **Brady TJ**, Murphy L, O'Colmain BJ, Beauchesne D, Daniels B, Greenberg M, House M, Chervin D. A meta-analysis of health status, health behaviors, and healthcare utilization outcomes of the Chronic Disease Self-Management Program. *Prev Chronic Dis* 2013; **10**: 120112 [PMID: 23327828 DOI: 10.5888/pcd10.120112.]

14 **Harrison M**, Reeves D, Harkness E, Valderas J, Kennedy A, Rogers A, Hann M, Bower P. A secondary analysis of the moderating effects of depression and multimorbidity on the effectiveness of a chronic disease self-management programme. *Patient Educ Couns* 2012; **87**: 67-73 [PMID: 21767927 DOI: 10.1016/j.pec.2011.06.007]

15 **Guilcher SJ**, Bereket T, Voth J, Haroun VA, Jaglal SB. Spanning boundaries into remote communities: an exploration of experiences with telehealth chronic disease self-management programs in rural northern ontario, Canada. *Telemed J E Health* 2013; **19**: 904-909 [PMID: 24134184]

16 **Griffiths C**, Motlib J, Azad A, Ramsay J, Eldridge S, Feder G, Khanam R, Munni R, Garrett M, Turner A, Barlow J. Randomised controlled trial of a lay-led self-management programme for Bangladeshi patients with chronic disease. *Br J Gen Pract* 2005; **55**: 831-837 [PMID: 16281998]

17 **Stone GR**, Packer TL. Evaluation of a rural chronic disease self-management program. *Rural Remote Health* 2010; **10**: 1203 [PMID: 20297869]

18 **Dongbo F**, Ding Y, McGowan P, Fu H. Qualitative evaluation of Chronic Disease Self Management Program (CDSMP) in Shanghai. *Patient Educ Couns* 2006; **61**: 389-396 [PMID: 15975756 DOI: 10.1016/j.pec.2005.05.002]

19 **Chan WL**, Hui E, Chan C, Cheung D, Wong S, Wong R, Li S, Woo J. Evaluation of chronic disease self-management programme (CDSMP) for older adults in Hong Kong. *J Nutr Health Aging* 2011; **15**: 209-214 [PMID: 21369669 DOI: 10.1007/s12603-010-0257-9]

20 **Elzen H**, Slaets JP, Snijders TA, Steverink N. Evaluation of the chronic disease self-management program (CDSMP) among chronically ill older people in the Netherlands. *Soc Sci Med* 2007; **64**: 1832-1841 [PMID: 17355901]

21 **Lorig K**, Ritter PL, Plant K. A disease-specific self-help program compared with a generalized chronic disease self-help program for arthritis patients. *Arthritis Rheum* 2005; **53**: 950-957 [PMID: 16342084 DOI: 10.1002/art.21604]

22  **Smith ML,** Ory MG, Ahn S, and Miles TP. Factors Associated with Women's Chronic Disease Management: Associations of Healthcare Frustrations, Physician Support, and Self-Care Needs. *J Aging Res* 2013; Article 982052

23 **Ory MG**, Ahn S, Jiang L, Smith ML, Ritter PL, Whitelaw N, Lorig K. Successes of a national study of the Chronic Disease Self-Management Program: meeting the triple aim of health care reform. *Med Care* 2013; **51**: 992-998 [PMID: 24113813 DOI: 10.1097/MLR.0b013e3182a95dd1]

24 **Brady TJ,** Murphy L. Sorting through the evidence for the arthritis self-management program and the chronic disease self-management program: Executive summary of ASMP/CDSMP meta-analysis [Internet]; 2011 (Accessed on 2nd December 2013). Available from: http: //www.cdc.gov/arthritis/docs/ASMP-executive-summary.pdf.

25 **Barlow JH**, Wright CC, Turner AP, Bancroft GV. A 12-month follow-up study of self-management training for people with chronic disease: are changes maintained over time? *Br J Health Psychol* 2005; **10**: 589-599 [PMID: 16238867 DOI: 10.1348/135910705X26317]

26 **Kennedy A**, Reeves D, Bower P, Lee V, Middleton E, Richardson G, Gardner C, Gately C, Rogers A. The effectiveness and cost effectiveness of a national lay-led self care support programme for patients with long-term conditions: a pragmatic randomised controlled trial. *J Epidemiol Community Health* 2007; **61**: 254-261 [PMID: 17325405 DOI: 10.1136/jech.2006.053538]

27 **Goeppinger J**, Armstrong B, Schwartz T, Ensley D, Brady TJ. Self-management education for persons with arthritis: Managing comorbidity and eliminating health disparities. *Arthritis Rheum* 2007; **57**: 1081-1088 [PMID: 17665471 DOI: 10.1002/art.22896]

28 **Lorig K**, Ritter PL, Ory MG, Whitelaw N. Effectiveness of a generic chronic disease self-management program for people with type 2 diabetes: a translation study. *Diabetes Educ* 2013; **39**: 655-663 [PMID: 23782621 DOI: 10.1177/0145721713492567]

29 **Ory MG**, Ahn S, Jiang L, Lorig K, Ritter P, Laurent DD, Whitelaw N, Smith ML. National study of chronic disease self-management: six-month outcome findings. *J Aging Health* 2013; **25**: 1258-1274 [PMID: 24029414 DOI: 10.1177/0898264313502531]

30 **Altman DG,** Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, CONSORT GROUP: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. *Ann Intern Med* 2001; **134:** 663-694 [DOI: 10.7326/0003-4819-134-8-200104170-00012]

31 **Forjuoh SN**, Bolin JN, Huber JC, Vuong AM, Adepoju OE, Helduser JW, Begaye DS, Robertson A, Moudouni DM, Bonner TJ, McLeroy KR, Ory MG. Behavioral and technological interventions targeting glycemic control in a racially/ethnically diverse population: a randomized controlled trial. *BMC Public Health* 2014; **14**: 71 [PMID: 24450992 DOI: 10.1186/1471-2458-14-71]

32 **Centers for Disease Control and Prevention.** Sorting through the evidence for the Arthritis Self-Management Program and the Chronic Disease Self-Management Program: Executive summary of ASMP/CDSMP meta-analysis. 2013 (Accessed on 27th January 2013) Available at: http: //www.cdc.gov/arthritis/docs/asmp-executive-summary.pdf .

33 **Sevick MA**, Trauth JM, Ling BS, Anderson RT, Piatt GA, Kilbourne AM, Goodman RM. Patients with Complex Chronic Diseases: perspectives on supporting self-management. *J Gen Intern Med* 2007; **22 Suppl 3**: 438-444 [PMID: 18026814 DOI: 10.1007/s11606-007-0316-z]

34 **Lorig K**, Ritter PL, Villa F, Piette JD. Spanish diabetes self-management with and without automated telephone reinforcement: two randomized trials. *Diabetes Care* 2008; **31**: 408-414 [PMID: 18096810 DOI: 10.2337/dc07-1313]

**P-Reviewers:** Ricardo GM, Zhang Q **S-Editor:** Song XX **L-Editor:** **E-Editor:**

**Table 1 Characteristics of study participants (*n* = 196)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | Controls  (*n* = 95) | | CDSMP  (*n* = 101) | | *P-*value |
|  | | No. | % | No. | % |
| Age Group, yr | |  |  |  |  | 0.32 |
|  | 30-44 | 15 | (15.8) | 12 | (11.9) |  |
|  | 45-64 | 55 | (57.9) | 69 | (68.3) |  |
|  | ≥ 65 | 25 | (26.3) | 20 | (19.8) |  |
| Gender | |  |  |  |  | 0.74 |
|  | Female | 53 | (55.8) | 54 | (53.5) |  |
|  | Male | 42 | (44.2) | 47 | (46.5) |  |
| Hispanic | |  |  |  |  | 0.46 |
|  | Yes | 15 | (15.8) | 20 | (19.8) |  |
|  | No | 80 | (84.2) | 81 | (80.2) |  |
| Minoritya | |  |  |  |  | 0.32 |
|  | Yes | 32 | (33.7) | 41 | (40.6) |  |
|  | No | 63 | (66.3) | 60 | (59.4) |  |
| Race/Ethnicity | |  |  |  |  | 0.60 |
|  | African American | 17 | (17.9) | 21 | (20.8) |  |
|  | Hispanic | 15 | (15.8) | 20 | (19.8) |  |
|  | Neither Hispanic or African-American | 63 | (66.3) | 60 | (59.4) |  |
| Income | |  |  |  |  | 0.40 |
|  | < $15000 | 9 | (10.5) | 12 | (13.6) |  |
|  | $15000 - $24999 | 16 | (18.6) | 11 | (12.5) |  |
|  | $25000 - $49999 | 30 | (34.9) | 41 | (46.6) |  |
|  | $50000 - $75000 | 17 | (19.8) | 12 | (13.6) |  |
|  | > $75000 | 14 | (16.3) | 12 | (13.6) |  |
| Education | |  |  |  |  | 0.48 |
|  | High graduate or less | 25 | (26.3) | 26 | (25.7) |  |
|  | Some college/vocation school | 36 | (37.9) | 46 | (45.5) |  |
|  | College graduate or higher | 34 | (35.8) | 29 | (28.7) |  |
| HbA1c (%), mean ± SD | | 9.2 | (1.6) | 9.4 | (1.7) | 0.48 |
| SBP (mm/Hg), mean ± SD | | 132.9 | (21.7) | 131.9 | (14.1) | 0.73 |
| DBP (mm/Hg), mean ± SD | | 75.8 | (13.6) | 79.4 | (9.8) | 0.05 |
| BMI (kg/m2), mean ± SD | | 33.9 | (7.7) | 33.5 | (8.0) | 0.70 |

1African American or Hispanic. HbA1c: Hemoglobin A1c; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index.

**Table 2** **Baseline diabetes self-care activities monitoring, health-related quality of life, pain and fatigue measures**

|  |  |  |  |
| --- | --- | --- | --- |
| Measure | Controls | CDSMP | *P* value |
| **Diabetes self-care activity monitoring (d/wk)** |  |  |  |
| 30 min of any physical activity? | 3.01 | 3.50 | 0.17 |
| Daily exercise session? | 2.23 | 2.53 | 0.40 |
| Test your blood sugar? | 4.22 | 4.38 | 0.70 |
| Test sugar # times provider recommends? | 3.58 | 3.29 | 0.50 |
| Check your feet? | 5.20 | 4.41 | 0.04 |
| Wash your feet? | 6.58 | 6.36 | 0.29 |
| Soak your feet? | 1.73 | 1.21 | 0.14 |
| Dry between your toes? | 5.21 | 5.37 | 0.68 |
| Inspect inside of shoes? | 3.25 | 2.43 | 0.06 |
| Follow a healthful eating plan? | 3.80 | 3.92 | 0.71 |
| Space carbohydrates evenly? | 3.25 | 3.12 | 0.74 |
| Eat ≥ 5 fruit/vegetable servings? | 3.80 | 3.44 | 0.30 |
| Eat high-fat products (red meat, full-fat diary)? | 3.63 | 3.63 | 0.98 |
| Eat packaged or bakery goods? | 2.05 | 2.16 | 0.71 |
| **Health related quality of life (d/mo)** |  |  |  |
| Physical health not good | 3.98 | 5.96 | 0.07 |
| Mental health not good | 4.09 | 4.72 | 0.56 |
| Physical/mental health hindered usual activities | 1.82 | 3.65 | 0.05 |
| **Pain and fatigue measures (scale 1-10)** |  |  |  |
| Average daily pain in the past 2 wk | 3.74 | 3.74 | 1.00 |
| Average daily fatigue in the past 2 wk | 4.41 | 4.54 | 0.72 |

**Table 3** **Results from the linear mixed models**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Controls  (*n* = 95) | CDSMP  (*n* = 101) | Difference between the two groups |
|  | Mean  ± SE1 | Mean  ± SE1 | Mean  ± SE1 |
| Baseline | 9.018 ± 0.153 | 9.175 ± 0.149 | 0.157 ± 0.213 |
| 12 mo | 8.442 ± 0.160 | 8.615 ± 0.156 | 0.173 ± 0.218 |
| 12 mo – Baseline | -0.576 ± 0.093b | -0.559 ± 0.091b | 0.016 ± 0.112 |

1Adjusted means from linear mixed models. b*P* < 0.0001 for test *vs* H0: mean equals to 0.